Advertisement
Advertisement
GPCR
Structure Therapeutics Inc. - ADR
48.15
USDSponsored
+1.11
+2.36%
Mar 25, 15:59 UTC -4
Closed
After-Market
48.50
+0.35
+0.73%
GPCR Earnings Reports
Positive Surprise Ratio
GPCR beat 1 of 13 last estimates.
8%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.35
Implied change from Q4 25 (Revenue/ EPS)
--
/-71.31%
Implied change from Q1 25 (Revenue/ EPS)
--
/-56.79%
Structure Therapeutics Inc. - ADR earnings per share and revenue
On Feb 26, 2026, GPCR reported earnings of -1.22 USD per share (EPS) for Q4 25, missing the estimate of -0.47 USD, resulting in a -157.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.68% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an decrease of -71.31% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Structure Therapeutics Inc. - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Structure Therapeutics Inc. - ADR reported EPS of -$1.22, missing estimates by -157.06%, and revenue of $0.00, 0% as expectations.
How did the market react to Structure Therapeutics Inc. - ADR's Q4 2025 earnings?
The stock price moved down -2.68%, changed from $66.53 before the earnings release to $64.75 the day after.
When is Structure Therapeutics Inc. - ADR expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Structure Therapeutics Inc. - ADR's next earnings report?
Based on 12
analysts, Structure Therapeutics Inc. - ADR is expected to report EPS of -$0.35 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement